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Abstract.
Background: There is increasing evidence to suggest a tight relationship between cognitive impairment and falls in Parkinson’s
disease (PD). Here, we draw attention to a potentially significant flaw in the existent falls-related research, namely the apparent
exclusion of patients with cognitive impairment or dementia.
Objective: Our objective was to review all published, on-going or scheduled fall-related intervention studies, in order to
investigate the extent to which cognitively impaired individuals with PD were included in these studies.
Methods: We analyzed published controlled trials regarding falls and PD in commonly used databases, as well as relevant
ongoing clinical trials registered within the World Health Organization database, clinicaltrials.gov and the European Clinical
Trials Database.
Results: Fourteen of the fifteen published studies included had explicit cognitive exclusion criteria as part of their study protocol.
Most of the 54 on-going PD fall-related studies excluded patients with cognitive impairment.
Conclusions: This suggests that individuals with cognitive impairment or dementia are excluded from fall-related research
studies. We strongly recommend that future work in this area should include a representative sample of patients with PD,
including subjects with cognitive decline.
Keywords: Falls, Parkinson disease, rehabilitation, cognition, clinical trials
INTRODUCTION
Parkinson’sdisease(PD) isacomplexheterogeneous
neurodegenerativedisorder. Inorder tocapture theover-
all picture of PD, it is important to consider not only the
typical motor problems such as tremor, bradykinesia,
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ogia Clı´nica e Terapeˆutica, Faculdade de Medicina de Lisboa, Av.
Prof. Egas Moniz, 1649-028 Lisboa, Portugal. Tel.: +351 21
7802120; Fax: +351 21 7802129; E-mail: joaquimjferreira@gmail.
com.
postural instability, and levodopa-induced motor com-
plications, but also non-motor symptoms, such as pain,
depression and cognitive impairment. Mild cognitive
impairment(MCI)andPDdementia(PDD)arefrequent
and incidence increases with age, disease duration, and
disease severity [1]. Even though there is still some
debate regarding the definition, MCI is considered a
cognitive decline that is not normal for age but with
basically normal functional activities, and that appears
to place patients at risk of progressing to dementia
[1–3].
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A growing body of class II evidence suggests that
there is an increased risk of falls in the presence of cog-
nitive impairment [4–7] as well as in dementia [8, 9]
and this trend is present in both community-dwelling
and institutionalized older populations. An evidenced
based review from the American Academy of Neurol-
ogy (ANN) pooled data from five studies and indicated
an absolute risk of falling of 47% among individu-
als with dementia during study follow-up [6, 10–13].
Similar findings were reported in populations with PD
[14–17]. A randomized, placebo-controlled, crossover,
double-blind study demonstrated that one acetyl-
cholinesterase inhibitor, donepezil, may have some
symptomatic effect on cognitive deficits with a con-
comitant significant reduction in the number of falls in
non-demented individuals with PD [18].
A more restrictive protocol that reduces or elim-
inates cognitively impaired individuals from fall
intervention studies may have a substantive impact
on the representativeness of the study sample.
Consequently, current findings with respect to pharma-
cological [18] and non-pharmacological interventions
[19–22] may fall short in providing the best possible
evidence for appropriate management in individuals
with cognitive impairment and may not be able to
be extrapolated to this population. This methodolog-
ical flaw was recently also highlighted in the study
by Amar (2015) that defended that individuals with
PD with moderate cognitive impairment face complex
problems and warrant inclusion in falls research [23].
Ultimately, if individuals with MCI or dementia are at
greater risk for falls, they should be included in specific
fall-related research studies in order for the results of
these studies to be relevant and applicable to the types
of patients seen in actual clinical practice.
The primary goal of this review was to assess the
extent of inclusion of individuals with PD and with
MCI or dementia in published, on-going or in planning
clinical controlled trials which had falls and/or fall-
related outcomes.
MATERIALS AND METHODS
Study design: Systematic review
Literature search for published studies
We conducted a systematic search for all con-
trolled trials regarding pharmacologic and non-
pharmacological interventions for falls in PD that were
published as full text papers up to May 2015. We used
the electronic databases Medline, EMBASE, Cochrane
Library Central Database and PEDro using the MeSH
terms “PD”, or “Parkinson disease” AND “falls” AND
“intervention” AND “prevention” to complete the lit-
erature search. Full text copies of potentially relevant
trials were retrieved and their reference lists were
systematically checked.
Literature search for ongoing studies
We also analyzed the major characteristics of
ongoing clinical trials from the online open-access
World Health Organization (WHO-ICTRP), the Clini-
cal trial.gov database and the European Clinical Trials
database (EudraCT) that proposed to evaluate the effi-
cacy and/or safety of therapeutic interventions for the
prevention or management of falls in PD. Within these
databases, a search was performed for ongoing con-
trolled trials regarding PD and falls using the following
keywords: “Parkinson disease” AND “falls”. The stud-
ies were hand sorted to exclude duplicate entries and
studies that were not related to therapeutic interven-
tions for falls in PD. Data regarding study variables,
particularly exclusion on the grounds of cognitive
scores were extracted from each study.
Selection criteria for studies
We included published controlled trials regarding
therapeutic interventions or prevention of falls for indi-
viduals with PD with fall or fall related outcomes. The
type of participants in these interventions included:
individuals with a diagnosis of PD; any duration and
stage of PD; all ages; any drug, surgical or rehabilita-
tion interventions; and any duration of intervention.
Data extraction
From the published and the on-going trials reviewed
we searched the following information for source of
support:
a) General characteristics of the trials (scientific
study name or main identification number, year
of publication, authors, publication status, study
design, exclusion criteria related to cognition
status, control group, gait and falls related inclu-
sion criteria, drop-outs and adverse effects);
b) Characteristics of participants (number of par-
ticipants in each group, age, gender, diagnostic
criteria, disease severity measures);
c) Characteristics of interventions (type of inter-
vention - pharmacological, surgical, physio-
therapy/occupational/speech, dose, mode of
administration, duration of follow up);
J.M. Domingos et al. / Cognitive Impairment in Fall-Related Studies in Parkinson’s Disease 455
d) Characteristics of outcome measures (primary
outcome measure, secondary or other outcomes
and assessment method used for fall recording).
We determined the number of trials that excluded
participants due to cognitive impairment regardless of
the definition of cognitive impairment used. Extrac-
tion of all data was conducted by two independent
reviewers (JMD and CG), with disagreements resolved
by a third rater (JD).
RESULTS
Characteristics of included studies
Regarding the published intervention-related
studies, the search in the databases identified 722
records, of which 15 trials met the inclusion criteria
for this review, in which a total of 1380 individuals
participated (Fig. 1). There were 14 trials evaluating
a non-pharmacological intervention and 1 trial for
pharmacological intervention. Thirteen of the trials
[19, 20, 22, 24–32, 45] had a parallel group design and
two cross-over trials [18, 21]. Chung et al. [18] was
a randomized, placebo-controlled, crossover design
and double-blind trial. All trials were published in a
full paper format. The trial characteristics of the 15
controlled trials that met our pre-defined inclusion
criteria are summarized in Table 1.
Regarding the ongoing clinical trials, as of May,
2015, there were 19 registered trials regarding falls in
PD in the WHO-ICTRP that met the inclusion criteria.
From the European Clinical Trials database 2 addi-
tional clinical pharmacological trials were included.
Fig. 1. Flow diagram for data extraction.
Within the ClinicalTrials.gov database there were 33
registered trials regarding falls in PD after been when
crossed check. The main characteristics of all on-going
trials are described in Table 2.
Participant characteristics
Participant characteristics of published trials were
variable (Table 1). A clear diagnosis of PD was pre-
dominant with the exception of one published trial [26]
which instead included participants with a diagnosis
of Parkinsonism and no delineation of the character-
istics of that terminology. The majority of the studies
included individuals in stage II-III on the Hoehn and
Yahr scale although six studies also included individu-
als in stage I [26]. The mean age of participants across
trials ranged from 63 (±8.0) and 74, 5 (±9.7) years.
Fall history was a common inclusion criteria ranging
from 2 or more falls in the previous 12 months to 2 or
more near falls per week.
Participant characteristics of the on-going trials
were also widely variable and are described in Table 2.
Exclusion criteria related to cognitive status
Fourteen of the fifteen published intervention-
related studies (n = 14) had explicit cognition exclusion
criteria included as part of the study protocol. One
study did not mention cognition aspects in the exclu-
sion or inclusion criteria [24]. Forty-two of the
fifty-four of the on-going studies registered in the
WHO, EudraCT and Clinical Trials.gov database also
had explicit cognition exclusion criteria.
Exclusion based on cognitive scores indicative of
dementia was common. Eleven published and thirty-
one on-going studies included in this review excluded
participants based on a low Mini Mental Status Exam-
ination (MMSE) score (with the cutoff scores ranging
from “less than 23” to “25 or lower”) (N = 42). Harro
(2014) excluded participants if they had impaired cog-
nitive functioning evidenced by a score of 20 or less on
the Saint Louis Mental Status Examination (SLUMS)
[27]. None of the studies specifically considered mild
cognitive impairment as part of the exclusion criteria.
Due to the consistent nature of the exclusion of
individuals with MCI or dementia, we were unable to
analyze possible variables or characteristics that could
be related to the rate of exclusion by MCI or dementia.
Intervention characteristics
The interventions being investigated were widely
varied and predominately studies of non-pharma
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Table 2
Ongoing Clinical trials characteristics with individuals with Parkinson´s disease regarding falls
interventions from the WHO, EudraCT and Clinical trial.gov databases
Source Number of clinical studies
WHO EudraCT Clinical trial.gov
Number of studies 19 2 33
Study design
Randomized control trial 16 2 27
Controlled trial 3 0 6
Exclusion by cognition status
Excluded based on mini mental score 12 0 19
Excluded based on other cognitive parameter 4 1 6
Missing data 3 1 8
Type of Intervention
Pharmacological 2 2 8
Surgical 0 0 1
Physiotherapy/occupational 17 0 24
Sample size
Inferior 50 8 0 19
Between 50-100 3 0 3
Superior 100 8 2 11
Disease Stage
Stage I-II 0 1 4
Stage II-III 3 1 4
Stage III-IV 7 0 14
Stage V 0 0 0
Missing data 9 0 11
Method of falls data collecting
Diaries 6 0 7
Calendars 1 0 1
Post cards 0 0 0
Phone calls 1 0 2
Questionnaires 11 0 7
Missing data 0 2 16
Fall outcome measure
Primary outcome 8 1 5
Secondary outcome 4 1 12
Study duration
Inferior 8 weeks 4 0 5
Between 8-24 weeks 4 0 17
Superior to 24 weeks 8 2 9
Missing data 3 0 2
Recruiting Status
Recruiting 5 0 12
Non recruiting 2 0 2
Completed 12 0 13
Other 0 2 6
WHO- www.who.int./trialsearch/AdvSearch.aspx. EudraCT – www.clinicaltrialsregister.eu/ctr-search/
search. Clinical trial.gov - www.clinicaltrialsregister. eu/ctr-search/search.
cological (i.e. rehabilitation based) interventions with
only one pharmacological intervention [18] of a total of
15 published intervention-related studies used in this
review.
In the on-going studies, 41 were non-pharma
cological while only 12 were pharmacologically based.
Physiotherapy was the primary component of
the non-pharmacological interventions and included
treadmill training alone or with turning exercises
[15, 19, 27], cueing gait program [14, 27], strength and
balance programs [12, 13, 16, 28, 29], home-based pro-
grams [16, 30], teaching strategies for falls preventions
[13], tai chi and exercise programs [17], muscle power
training [30, 45], technology-assisted balance and gait
training [31], and hydrotherapy perturbation-based
balance training [32].The duration of the interventions
varied from minimum 6 weeks to 6 months. The only
pharmacological intervention consisted of 6 weeks of
donepezil or placebo with a 3 week washout between
phases.
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Common outcome measures used for falls
assessment
Outcome measures related to falls included: rates
of falling, frequency of falls, frequency of near falls,
fear of falling, number of fallers, and number of injuri-
ous falls. This was repeatedly measured by using falls
diaries, calendars, postcards, and telephone reminders
or interviews.
Drop-outs and adverse effects
There were limited reporting regarding adherence,
adverse events and drop-outs. The study by Nieuwboer
et al. [21] reported that one participant dropped out 3
weeks after randomization due to a necessary change
of drug. Ashburn et al. [20] reported that drop-outs
occurred in the intervention group (1 partner unwell,
1 disliked exercises, 1 died, 1 withdrew for no reason,
1 withdrew due to falls) and control group (4 unwell,
2 died, and 1 moved away). Allen et al. [19] described
that the exercise group had no major adverse events but
had 3 drops outs, 1 due to no longer wished to partici-
pate and 2 developed health problems unrelated to the
intervention. Chung et al. [18] reported that 4 partici-
pants dropped out before the second phase (2 on active
drug, 1 each during placebo phase and washout) and
were excluded from the data analysis. Additionally,
before the second crossover period, 2 more participants
withdrew but were included in the analysis. Goodwin
et al. [24] reported one pelvic fracture by a control
group participant.
DISCUSSION
There is a lack of inclusion of individuals with PD
with mild cognitive impairment and/or dementia in
fall-related intervention studies and this continues to
be prevalent in currently ongoing and scheduled trials.
This may represent a serious methodological flaw with
implications regarding the interpretation and clinical
application of current and future fall interventions. This
ultimately may lead to – at least partly – inadequate
treatment recommendations for those who “really” fall
(i.e. the cognitively impaired patients), and may really
be useful only for a minority of the target population.
Cognitive status factors have long been recognized
as having an important impact on management in
PD but are frequently not addressed in the con-
text of physiotherapy. In particular, impaired attention
and executive function may exacerbate the difficulties
with multitasking and contribute to falls. Cognitively
impaired individuals often lose the capacity to prior-
itize tasks and when performing a dual task activity,
they tend to reduce priority and/or attention to the gait
or balance task, and focus more upon the completion of
the secondary task [33]. This places these individuals
at an increased risk for falling under complex multi-
task circumstances testing [34]. In a study by Allcock
et al. [35], it was shown that the association of atten-
tional deficits with postural instability translates into
increased fall frequency measured prospectively over
a 1 year study period. Another 12-month longitudinal
cohort study of 102 older people without dementia (52
subjects with PD and 50 age and sex-matched controls)
concluded that mild cognitive impairment might con-
tribute to falls risk beyond conventional risk factors in
older people with and without PD [14].
These findings raise a fundamental question. Should
individuals with MCI and/or dementia be more widely
considered or even recruited for specific fall interven-
tion studies? Cognitively impaired individuals may
be less able to comply with certain treatment and
assessment components of trials and may also have
higher adverse events and drop-out rates. Addition-
ally, the design of clinical trials typically attempts
to minimize confounding variables. Certain forms of
cognitive impairment may independently contribute to
falls (e.g., impulsive movements related to frontal lobe
dysfunction). Hence, excluding cognitive impairment
is defensible on these bases and so doing interventions
to reduce falls should initially be shown as effica-
cious among non-demented PD patients. Subsequently,
the strategy could be applied to those with cognitive
impairment. Burton et al., (2015) [36] recently did a
systematic review and meta-analysis to evaluate the
effectiveness of exercise programs to reduce falls in
older people with dementia who are living in the com-
munity. Three RCTs [37–39], with high quality and one
single-group pre- and post-test pilot study [40] were
included. Participants were included if they had a diag-
nosis by a doctor/specialist, or a validated test, such
as the Mini Mental State Examination (MMSE), Saint
Louis Mental Status Examination (SLUMS), the Clin-
ical Dementia Rating Scale, or the National Institute
of Neurological and Communicative Disorders and
Stroke, Alzheimer’s Disease and Related Disorders
Association (NINCDS-ADRDA) Alzheimer’s criteria.
Results from this review suggested that an exercise pro-
gram may potentially assist in preventing falls of older
people with dementia living in the community. If such
inclusion is possible in people without PD but with
dementia, it is plausible to think it can and should also
be applied to PD patients with cognitive impairment.
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A better understanding of the reasons that underlie
the exclusion of individuals with cognitive impaired
may allow clinicians and researchers to better iden-
tify possible solutions to overcome barriers associated
to this exclusion. Due to the consistent nature of the
exclusion of individuals with MCI or dementia in our
review, we were unable to objectively analyze or iden-
tify any potential variables/characteristics (i.e. study
type, number of participants, study duration, etc.) that
could be related to the rate of exclusion by MCI or
dementia. Additionally, the information provided by
the WHO-ICTRP and in published trials was limited
and insufficient to allow for a profound analysis of
possible justifications for exclusion due to cognitive
impairments. However, an important factor has to be
noted. From our review, the reason for exclusion is
dementia, as screened by tests of global cognitive dys-
function (i.e. Mini-Mental State Examination <24 and
UPDRS part I). Different data collection methods for
cognition are an important future line of research in this
area because instruments such as the MMSE may not
identify specific cognitive deficits, such as executive
and attentional deficits which are the type of frontal
lobe deficits that are more impaired in fallers [41].
Alternative options could include the Montreal Cogni-
tive Assessment (MoCA), which is sensitive to frontal
lobe dysfunction and has been shown to be effective as
a bedside test for evaluating the risk of falls [42].
Future studies should attempt to design assessment
and intervention procedures that include individu-
als with cognitive limitations by considering several
strategies. Screening for cognitive deficits should rou-
tinely be included in the work-up of individuals with
falls so clinicians can become aware of the test-
ing with regards to the individuals profile and cross
reference this data with physical capacity. Actively
involving carers in monitoring and encouraging par-
ticipation between therapist visits for the assigned
exercise program was identified as a facilitating factor
for inclusions of individuals with dementia [38, 39].
Participants and families may be more likely to enter
a clinical trial if they properly understand the poten-
tial health benefits (e.g. improved quality of life) that
could be realized via free high-quality treatment and
follow-up by expert clinicians as part of the study.
Difficulties associated with traveling to a facility may
be minimized if performing the follow-up evaluations
in the participant’s home is considered. Incorporat-
ing telemedicine and/or remote monitoring may also
enhance the ability of this population to participate in
many studies. Targeted cognitive training may offer a
novel treatment option for falls that is worthy of an
increased research and clinical focus. If the degree of
cognitive impairment can affect the success of inter-
ventions for falls prevention [43]; cognitive training
interventions may also be considered of particular
interest to reduce this limitation as it may be able
to improve cognitive processes thus reducing falls.
Additionally, a study by Allan (2009) suggested that
to prevent falls in mild-moderate dementia, possible
management strategies could also include management
of the potentially modifiable factors such as symp-
tomatic orthostatic hypotension, autonomic symptoms
and depression instead of prioritising strength and bal-
ance exercises that are more difficult for those with
cognitive impairment to adhere [44]. Finally, appro-
priate resource support including financial support for
such trials that recognizes the potential extra workload
involved might better facilitate this recruitment. The
existence of specific guidelines for recruiting cogni-
tive impaired people may also increase the likelihood
of researchers to recruit these individuals.
CONCLUSION
In conclusion, our findings suggests that due to the
historical and ongoing exclusion of individuals with
cognitive impairments, it is unclear if some interven-
tion approaches for falls are effective and safe for
this population. We highlight the substantial impact
of restrictive protocol exclusion criteria on cognitive
impaired PD patients. Even though participation of
individuals with cognitive impairment in clinical tri-
als may not always be desirable or feasible, it is still
important to determine if they are disproportionately
disqualified from participation and as a result, under-
represented in these trials, particularly in relationship
to their respective motor problems.
Increasing participation of this population in clinical
trials is critical in order to increase the external validity
of the studies.
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